Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs... Show more
a biopharmaceutical company which provides therapies for rare and orphan diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To KRYS | 1D Price Change % | ||
|---|---|---|---|---|
| KRYS | 100% | +0.42% | ||
| VCYT - KRYS | 44% Loosely correlated | -2.76% | ||
| AXON - KRYS | 43% Loosely correlated | +0.10% | ||
| ACAD - KRYS | 42% Loosely correlated | +0.32% | ||
| REPL - KRYS | 39% Loosely correlated | -2.42% | ||
| CADL - KRYS | 39% Loosely correlated | -6.93% | ||
More | ||||
The 10-day moving average for KRYS crossed bullishly above the 50-day moving average on August 31, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 261 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 195 of 248 cases where KRYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 81 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 42 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
KRYS moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
KRYS broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.553) is normal, around the industry mean (19.994). P/E Ratio (43.458) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (23.866) is also within normal values, averaging (427.627).